Trial Profile
A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children With Relapsed Acute Myeloid Leukemia (AML)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Cytarabine/daunorubicin (Primary) ; Cytarabine; Cytarabine; Filgrastim; Filgrastim; Fludarabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 01 Aug 2023 Status changed from active, no longer recruiting to completed.
- 30 Mar 2021 According to a Jazz Pharmaceuticals media release, the U.S. Food and Drug Administration (FDA) approved a revised label for Vyxeos (daunorubicin and cytarabine) to include a new indication to treat newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in pediatric patients aged one year and older.The approval of Vyxeos for this indication is supported by safety data from two single-arm trials (AAML1421 and CPX-MA-1201).
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology.